Data from Immunoregulation and Clinical Implications of ANGPT2/TIE2⁺ M-MDSC Signature in Non–Small Cell Lung Cancer

<div>Abstract<p>Myeloid-derived suppressor cells (MDSC) promote immunosuppression and are a target in the field of immuno-oncology. Accumulation of MDSCs is associated with poor prognosis and resistance to immunotherapy for several cancers. Here, we describe an accumulation of a subset of circulating monocytic MDSCs (M-MDSC) overexpressing TIE2, the receptor for angiopoietin-2 (ANGPT2), in patients with non–small cell lung cancer (NSCLC). Greater numbers of circulating TIE2⁺ M-MDSCs were detected in patients with NSCLC compared with healthy subjects, and this accumulation correlated with ANGPT2 concentration in blood. The presence of an ANGPT2-rich environment was associated with impairment of preexisting T-cell responses against tumor-associated antigens (TAA) in patients with NSCLC. We demonstrated that ANGPT2 sensitizes TIE2⁺ M-MDSCs such that these cells suppress TAA-specific T cells. In patients with NSCLC, upregulation of the ANGPT2/TIE2⁺ M-MDSC signature in blood was associated with a poor prognosis. Our results identify the ANGPT2/TIE2⁺ M-MDSC axis as a participant in tumor immune evasion that should be taken into account in future cancer immunotherapy.</p></div>